NCT00052000 (Clinical Trial / MLN-2704)

Study Title
A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer (NCT00052000)

Trial Description
This is the first study of MLN-2704, also known as MLN 591-DM1 conjugate,  administered to humans. The purpose of the study is to determine the highest dose of MLN-2704 that can be given safely to patients with prostate cancer, and to identify any side effects associated with taking the drug. This study will also evaluate how MLN-2704 is taken up (absorbed), broken down (metabolized) and eliminated (excreted) by the body. This process is called pharmacokinetic analysis.

This trial is sponsored by Millennium Pharmaceuticals [1]

Study Data

  • Condition: Prostate Cancer
  • Interventions:
    • Drugs used in this trial
      • MLN-2704 (MLN 591-DM1)
  • Phase: I
  • Estimated Enrollment: 29
  • Study Start Date: November 2002
  • Last verified: 2007

Study Schematic 

(Coming soon)

Click here to Return to Drug map


Last Editorial review: August 10, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.